Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-08-29FDA Approved: ZANAFLEX — Supplemental Application (Covis Pharma US, Inc)
The FDA approved a supplemental application for ZANAFLEX (tizanidine hydrochloride) submitted by Covis Pharma US, Inc.
-
FDA approval · 2014-08-28FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
The FDA has approved a supplemental application for Avonex (interferon beta-1a) filed by Biogen.
-
FDA approval · 2014-08-22FDA Approved: AMPYRA — Supplemental Application (Merz Pharmaceuticals, LLC)
The FDA approved a supplemental application for AMPYRA (dalfampridine) from Merz Pharmaceuticals, LLC.
-
FDA approval · 2014-08-22FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCl) submitted by Novartis Pharmaceuticals Corporation. The action updat…
-
FDA approval · 2014-08-18FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for Tecfidera (dimethyl fumarate), resulting in an approved modification to its labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-08-15FDA Approved: PLEGRIDY PEN — Original Application (Biogen Inc.)
The FDA approved Plegridy Pen (peginterferon beta-1a) from Biogen in an original application, making it a self-administered disease-modifyin…
-
FDA approval · 2014-04-24FDA Approved: REBIF — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for Rebif (interferon beta-1a) from EMD Serono, Inc.
-
FDA approval · 2014-04-17FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis, approving a change to the product's labeling/indication…
-
FDA approval · 2014-01-28FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approves a supplemental application for Betaseron (interferon beta-1b) from Bayer HealthCare Pharmaceuticals Inc., approving changes to …
-
FDA approval · 2014-01-28FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for COPAXONE (glatiramer acetate) submitted by Teva Neuroscience, Inc.
-
FDA approval · 2013-12-06FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved a supplemental application for Copaxone (glatiramer acetate) submitted by Teva Neuroscience, Inc.
-
FDA approval · 2013-11-07FDA Approved: ZANAFLEX — Supplemental Application (Covis Pharma US, Inc)
FDA approved a supplemental application for ZANAFLEX (tizanidine hydrochloride) from Covis Pharma US, Inc., indicating a labeling update as …
-
FDA approval · 2013-09-24FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Kesimpta (ofatumumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2013-09-05FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved a supplemental application for COPAXONE (glatiramer acetate) from Teva Neuroscience, Inc.
-
FDA approval · 2013-06-28FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for BETASERON (interferon beta-1b) by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2013-06-18FDA Approved: AMPYRA — Supplemental Application (Merz Pharmaceuticals, LLC)
FDA approved a supplemental application for AMPYRA (dalfampridine) from Merz Pharmaceuticals, LLC. The action authorizes changes to the prod…
-
FDA approval · 2013-05-28FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GILENYA (fingolimod HCl) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2013-05-24FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)
The FDA approved a Biogen supplemental application for TYSABRI (Natalizumab). The action indicates a modification/expansion of the product l…
-
FDA approval · 2013-04-19FDA Approved: REBIF — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for Rebif (interferon beta-1a) submitted by EMD Serono, Inc.
-
FDA approval · 2013-03-27FDA Approved: TECFIDERA — Original Application (Biogen Inc.)
FDA granted approval of Tecfidera (dimethyl fumarate) from Biogen for the treatment of relapsing forms of multiple sclerosis.
-
FDA approval · 2013-03-19FDA Approved: ZANAFLEX — Supplemental Application (Covis Pharma US, Inc)
FDA approved a supplemental application for ZANAFLEX (tizanidine hydrochloride) from Covis Pharma US, Inc.
-
FDA approval · 2013-03-13FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
The FDA approved a supplemental application for AVONEX (interferon beta-1a) submitted by Biogen.
-
FDA approval · 2013-03-08FDA Approved: ZANAFLEX — Supplemental Application (Covis Pharma US, Inc)
The FDA approved a supplemental application for Zanaflex (tizanidine hydrochloride) submitted by Covis Pharma US, Inc., updating the labelin…
-
FDA approval · 2013-03-08FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved a supplemental application for COPAXONE (glatiramer acetate) submitted by Teva Neuroscience, Inc.
-
FDA approval · 2013-03-06FDA Approved: LIORESAL (BACLOFEN) — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Lioresal (baclofen) from Amneal Pharmaceuticals LLC, enabling changes to the product labeling fo…